Pqr, glad to hear you agree on the patients. They are the ones that need this sooner rather than later - not the value of my portfolio Imo when they published the interim data I believed at that point it showed adequate incremental improvement to go for approval. Once the new endpoints were published on the European and UK sites I thought they should immediately go for it as to me there is no doubt enough for approval